146 related articles for article (PubMed ID: 26002144)
1. Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications.
Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
Gastric Cancer; 2016 Apr; 19(2):421-430. PubMed ID: 26002144
[TBL] [Abstract][Full Text] [Related]
2. Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer.
Ock CY; Lee KW; Kim JW; Kim JS; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Kim WH; Bang YJ; Oh DY
Clin Cancer Res; 2015 Jun; 21(11):2520-9. PubMed ID: 25712681
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
4. Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication.
Park S; Ha S; Kwon HW; Kim WH; Kim TY; Oh DY; Cheon GJ; Bang YJ
J Nucl Med; 2017 Jun; 58(6):899-904. PubMed ID: 28572288
[TBL] [Abstract][Full Text] [Related]
5. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
[TBL] [Abstract][Full Text] [Related]
6. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer.
Jiménez-Fonseca P; Carmona-Bayonas A; Sánchez Lorenzo ML; Plazas JG; Custodio A; Hernández R; Garrido M; García T; Echavarría I; Cano JM; Rodríguez Palomo A; Mangas M; Macías Declara I; Ramchandani A; Visa L; Viudez A; Buxó E; Díaz-Serrano A; López C; Azkarate A; Longo F; Castañón E; Sánchez Bayona R; Pimentel P; Limón ML; Cerdá P; Álvarez Llosa R; Serrano R; Lobera MPF; Alsina M; Hurtado Nuño A; Gómez-Martin C
Gastric Cancer; 2017 May; 20(3):465-474. PubMed ID: 27599830
[TBL] [Abstract][Full Text] [Related]
8. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.
Terashima M; Kitada K; Ochiai A; Ichikawa W; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M;
Clin Cancer Res; 2012 Nov; 18(21):5992-6000. PubMed ID: 22977193
[TBL] [Abstract][Full Text] [Related]
9. A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer.
Arigami T; Matsushita D; Okubo K; Shimonosono M; Sasaki K; Tsuruda Y; Kita Y; Tanabe K; Mori S; Yanagita S; Uenosono Y; Nakajo A; Kurahara H; Ohtsuka T
Surg Today; 2022 Dec; 52(12):1721-1730. PubMed ID: 35543754
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment.
Shitara K; Yatabe Y; Matsuo K; Sugano M; Kondo C; Takahari D; Ura T; Tajika M; Ito S; Muro K
Gastric Cancer; 2013 Apr; 16(2):261-7. PubMed ID: 22797858
[TBL] [Abstract][Full Text] [Related]
12. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.
Cho J; Jeong J; Sung J; Sung CO; Kim KM; Park CK; Choi MG; Sohn TS; Bae JM; Kim S
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S477-84. PubMed ID: 23274580
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.
Li Q; Jiang H; Li H; Xu R; Shen L; Yu Y; Wang Y; Cui Y; Li W; Yu S; Liu T
Oncotarget; 2016 Aug; 7(31):50656-50665. PubMed ID: 27409420
[TBL] [Abstract][Full Text] [Related]
14. Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer.
Chen R; Zhou X; Liu J; Huang G
J Nucl Med; 2016 Jul; 57(7):1040-4. PubMed ID: 26966162
[TBL] [Abstract][Full Text] [Related]
15. The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy.
Wang C; Guo W; Zhou M; Zhu X; Ji D; Li W; Liu X; Tao Z; Zhang X; Zhang Y; Li J
Clin Cancer Res; 2016 Apr; 22(7):1603-10. PubMed ID: 26607599
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
[TBL] [Abstract][Full Text] [Related]
17. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.
Personeni N; Baretti M; Bozzarelli S; Spaggiari P; Rubino L; Tronconi MC; Fumagalli Romario U; Rosati R; Giordano L; Roncalli M; Santoro A; Rimassa L
Gastric Cancer; 2017 May; 20(3):428-437. PubMed ID: 27530622
[TBL] [Abstract][Full Text] [Related]
18. Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China.
Shen GS; Zhao JD; Zhao JH; Ma XF; Du F; Kan J; Ji FX; Ma F; Zheng FC; Wang ZY; Xu BH
World J Gastroenterol; 2016 Jun; 22(23):5406-14. PubMed ID: 27340357
[TBL] [Abstract][Full Text] [Related]
19. Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer.
Ock CY; Oh DY; Lee J; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Gastric Cancer; 2016 Apr; 19(2):597-606. PubMed ID: 25749718
[TBL] [Abstract][Full Text] [Related]
20. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
Cho JH; Lim JY; Cho JY
World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]